Alkem Labs

Cipla, Alkem eye Rs 4,000 crore stake in India's largest stent manufacturer

India's largest stent manufacturer, Sahajanand Medical Technologies is also reportedly exploring a public listing on the domestic market

Alkem Labs Q1 results: Net profit jumps 91% to Rs 550 cr on robust sales

Alkem Laboratories on Friday said its consolidated net profit increased by 91 per cent to Rs 550 crore in the first quarter ended June 2024, aided by robust sales. The drug firm had reported a net profit of Rs 288 crore in the April-June quarter of last fiscal. Total income increased to Rs 3,152 crore in the first quarter as against Rs 3,033 crore in the year-ago period, Alkem Laboratories said in a regulatory filing. "We are happy that our efforts to improve profitability have started paying off, and we have seen a marked increase in margins during the quarter," Alkem Laboratories CEO Vikas Gupta said. The company is committed to maximise EBITDA margin by managing product mix, controlling costs, and taking advantage of the favourable raw material pricing environment, he added. "The domestic business is our stronghold, and we expect to build on it by furthering the growth of our large brands and bridging portfolio gaps. Simultaneously, we are also focusing on growing our business

Alkem Labs shares surge 5% on USFDA's VAI status for Baddi facility

Shares of Alkem Labs gain up to 4.77 per cent at Rs 5,250.30 per share on the BSE in Tuesday's intraday trade

How Alkem's 83-year-old founder is remaking India's 4th-largest pharma firm

Hailing from Okari, a remote village in Jehanabad district of Bihar, Singh and his brother, Samprada, moved to Mumbai in 1973 to start Alkem Laboratories with a seed capital of Rs 5 lakh

Alkem Labs slumps 7% post Q4 show; brokerages see downside up to 15%

On Wednesday, Alkem Laboratories reported a 313.9 per cent surge in its consolidated net profit, reaching Rs 293.5 crore in the quarter ending March 31, 2024

Alkem Labs sinks 14% to 3-month low on reports of tax evasion of Rs 1000 cr

Alkem Labs sinks on reports of tax evasion: The stock sank to an intra-day low of Rs 4,653 as of 1:15 pm on BSE, its lowest since December 5 when it closed at Rs 4,652

Results preview: India business to put a spring in pharma's step

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels

Stocks to watch: Axis Bank, Zee Ent, SpiceJet, RIL, Bharat Forge, Alkem Lab

Stocks to watch: Zee Entertainment has been barred from the futures and options (F&O) segment of the NSE; Olectra Greentech has developed a hydrogen bus in technical partnership with Reliance Ind

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Here is a Bull Spread Strategy on Alkem Labs by Nandish Shah of HDFC Sec

The stock price of Alkem Laboratories has broken out on the daily chart

Double-digit sales dip in anti-infective segment to weigh on Alkem Labs

Higher chronic sales, US market could offset some of the weakness in sales growth

Alkem Labs Q1 profit jumps 2-fold to Rs 423.2 cr, revenue up at Rs 2,004 cr

Consolidated revenue from operations of the company stood at Rs 2,003.49 crore for the quarter under consideration. It was Rs 1,849.50 crore for the same period a year ago, it added

Alkem Labs receives two USFDA observations for Baddi facility in Himachal

It notified the company's management of objectionable conditions at the facility

Centre may cap trade margins for drugs in stages; companies oppose plans

While the trade margins for branded generics are standardised by trade, the margins vary in the case of unbranded generics

Alkem Lab, Navin Fluorine: Five mid-cap stocks that are likely to gain 10%

The stock that hits a new lifetime high attracts more volumes resulting in higher price levels.

Alkem Labs Q2 net up 14% at Rs 327 cr on robust sales

Consolidated total income of the company stood at Rs 1,888.95 crore

Drug regulator finds Alkem Labs drug substandard, again

It's the third alert to be issued in the past one year for the anti-diabetic drug; but no recall this time

Alkem Labs tumbles on fudging charges

Germany's medical regulator has accused the Mumbai-based firm of data manipulation in some clinical trials

Alkem Labs dips after observations from UK-MHRA

The company said that UK-MHRA has made eight observations following inspection of its Taloja facility